Darleukin Recruiting Phase 3 Trials for Malignant Melanoma Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02938299Neoadjuvant L19IL2/L19TNF- Pivotal Study